|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Similarly, currently available proprotein convertase subtilisin kexin type 9 inhibitors-alirocumab and evolocumab-both reduce ASCVD risk in statin-treated patients with diabetes.
|
31521544 |
2020 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The safety of very low LDL-C concentrations and the link between LDL-C lowering and diabetes is also discussed.<b>Expert opinion</b>: PCSK9 monoclonal antibodies when added to background statin therapy, lowers LDL-C to previously unattainable levels.
|
31623472 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
This article reviews the underlying aetiology and pathophysiology of this dyslipidaemia and atherosclerosis in those with diabetes, provides insights from epidemiological and genetic studies, and current cardiovascular risk reducing interventions including novel therapies such as PCSK-9 inhibitors.
|
31002453 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to explore this issue in a prespecified analysis of the ODYSSEY OUTCOMES trial of the PCSK9 inhibitor alirocumab, assessing its effects on cardiovascular outcomes by baseline glycaemic status, while also assessing its effects on glycaemic measures including risk of new-onset diabetes.
|
31272931 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
PCSK9-targeted siRNA-driven strategies may provide a novel therapeutic option for managing dyslipidemia in the presence and absence of diabetes.
|
30487231 |
2019 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In patients with stable CAD, low PCSK9 plasma levels are associated with a particular metabolic phenotype (low HDL cholesterol, the metabolic syndrome, obesity, insulin resistance and diabetes) and diffuse non-obstructive coronary atherosclerosis.
|
31672148 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Statins remain first-line therapy in patients with diabetes, though newer therapies to reduce LDL-C have emerged, including ezetimibe as an add-on therapy to statins, and injectable PCSK9 inhibitors, both of which are safe and effective in diabetes.
|
31758270 |
2019 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, compared with ezetimibe, which was actively used as lipid-modifying therapy in the control group, PCSK9-mAbs seem to have a lower risk of incident diabetes (RR 0.60, 95% CI 0.37-0.99; p = 0.04).
|
31823301 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
In studies reporting data on MACE and mortality separately for individuals with and without diabetes, the effect of PCSK-9 did not appear to be affected by diabetes.
|
30485622 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although genetic variants associated with lower levels of LDL-C are also associated with an increased NOD risk, clinical trials with lipid-lowering drugs other than statins, namely ezetimibe or monoclonal antibodies against PCSK9, did not observe an increase of developing diabetes.
|
31029825 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite strong indications from genetic studies that PCSK9 inhibition should increase diabetes risk, no such effect has been observed in clinical trials, and in-vitro and in-vivo studies do not clarify this issue.
|
30199407 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Like mutations with loss of function in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene, inhibitors of PCSK9 (PCSK9i) may potentially favor the manifestation of diabetes.
|
29180351 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
PCSK9 inhibition with evolocumab significantly reduced cardiovascular risk in patients with and without diabetes.
|
28927706 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multivariable Cox regression analysis showed that the third versus the first tertile of PCSK9 (hazard ratio: 1.640; 95% confidence interval: 1.117 to 2.407; p = 0.012), female sex, age, diabetes, smoking, heart failure, previous cerebrovascular and cardiac events, digoxin use, and total cholesterol to high-density lipoprotein cholesterol ratio were associated with CVEs.
|
28911508 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Monoclonal antibodies to PCSK9, given every 2-4 weeks by subcutaneous injection, have been shown to reduce LDL-cholesterol by 50-60% compared with placebo in individuals with and without diabetes.
|
28025677 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that sex could modify the effects of obesity and diabetes on PCSK9 in young adults.
|
28093849 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
We sought to investigate the associations of LDL cholesterol-lowering PCSK9 variants with type 2 diabetes and related biomarkers to gauge the likely effects of PCSK9 inhibitors on diabetes risk.
|
27908689 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
PCSK9 and diabetes: is there a link?
|
28111330 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effect of proprotein convertase subtilisin/kexin type 9 inhibition on new-onset diabetes, glycemia, and weight remains unclear.
|
28844508 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is an emerging role for the recently developed proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in diabetes, as these agents further reduce serum cholesterol and clinical cardiovascular events beyond the maximum tolerated statin therapy.
|
28871349 |
2017 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Plasma PCSK9 levels were measured in 195 people with T1D (mean age 38.8 years, mean diabetes duration 17.2 years, mean glycated haemoglobin [HbA1c] 8.3%), who were free of any lipid-lowering agent.
|
27804190 |
2017 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, variants in PCSK9 had approximately the same effect as variants in HMGCR on the risk of cardiovascular events and diabetes per unit decrease in the LDL cholesterol level.
|
27959767 |
2016 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We investigated the effect of PCSK9-InsLEU polymorphism on the incidence of prediabetes and diabetes.
|
26687699 |
2016 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Loci that encode targets of emerging LDL-C lowering drugs do not associate with dysglycemia, and this provides provisional evidence that new LDL-C lowering drugs (such as PCSK9 inhibitors) may not influence risk of diabetes.
|
26946290 |
2016 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We observed suggestive associations with the diabetes risk variant rs7961581 (p = 0.038; between TSPAN8 and LGR5) and rs5215 (p = 0.043; KCNJ11), the LDL risk variant rs11206510 (p = 0.045; PCSK9), as well as the AF risk locus ZFHX3.
|
24135527 |
2013 |